(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.15%.
Solid Biosciences's earnings in 2026 is -$215,271,000.On average, 15 Wall Street analysts forecast SLDB's earnings for 2026 to be -$196,802,849, with the lowest SLDB earnings forecast at -$261,302,575, and the highest SLDB earnings forecast at -$181,646,139. On average, 16 Wall Street analysts forecast SLDB's earnings for 2027 to be -$181,355,952, with the lowest SLDB earnings forecast at -$233,957,995, and the highest SLDB earnings forecast at -$157,036,017.
In 2028, SLDB is forecast to generate -$133,073,236 in earnings, with the lowest earnings forecast at -$192,505,844 and the highest earnings forecast at -$51,564,065.